CME LIVE OPEN ACCESS

Journal of Cancer Research

Research Article

Novel Oncology Drug Development Strategies in the Era of Personalized Medicine

Rehan Haider[*1], **Geetha Das**[2]

[1,2]*Department of Pharmacy University of Karachi, Pakistan, Riggs Pharmaceutical Karachi.*

Corresponding Author: Rehan Haider, Department of Pharmacy University of Karachi, Pakistan. Riggs Pharmaceutical Karachi.

Received: 2023 Aug 06 **Accepted:** 2023 Aug 25 **Published:** 2023 Sep 03

Abstract

The sphere of oncology drug improvement has experienced a transformative shift over the last couple of years because of the emergence of custom-designed remedies. With deeper knowledge of most cancer biology, the traditional «one-period-fits-all» approach is giving way to innovative strategies that cater to person-affected trends. This summary aimed to identify novel oncology drug improvement techniques that have emerged in the era of customized medicine. First, this summary delves into improvements in genomic profiling and biomarker identification. Utilizing generation, together with subsequent technologies such as sequencing and liquid biopsies, researchers can now recognize precise genetic adjustments and biomarkers that influence tumor growth and metastasis. This file allows for the improvement of centered remedy alternatives designed to shape the perfect genetic profile of each affected individual›s maximum cancers, thereby increasing remedy efficacy and lowering negative results. Second, the precis will communicate the rise of immunotherapy in personalized oncology drug development. Immune checkpoint inhibitors and adoptive T-mobile restoration strategies have tested top notch top-notch fulfillment in treating positive sorts of cancer by unleashing the affected person›s immune system in opposition to tumor cells. Biomarker-driven character choice plays an important role in identifying people›s maximum opportunity to benefit from immuno therapies, enhancing favored reaction charges and patient results. The third aspect of this abstract is to explore the integration of real-world data and artificial intelligence (AI) in oncology drug development. Algorithms can identify patterns, predict treatment responses, and guide treatment decisions by harnessing large datasets from electronic health records, clinical trials, and patient registries. Such data-driven approaches will contribute to more informed and personalized treatment strategies for patients. Furthermore, this abstract highlights the significance of collaboration among academia, pharmaceutical groups, and regulatory bodies in shaping customized oncology drug development. Streamlined regulatory pathways and current-day medical trial designs facilitate the improvement and approval of centered healing techniques, allowing for well-timed admission to contemporary remedies for patients.

Key Words: Oncology, Drug development, Personalized Medicine, Genomic Profiling, Biomarkers Targeted Therapies, Immunotherapy, Immune Checkpoint Inhibitors, Adoptive T-cell Therapies Real-World Data, Artificial Intelligence (AI).

1. Introduction

In this era of personalized medicine, the focus of oncology drug development is shifting from classic chemotherapeutic drugs to rationally designed molecularly targeted agents (MTAs). This development has been accelerated by an improved understanding of the key features of human tumor biology, which have emerged over the last decade. A seminal paper by Hanahan and Weinberg (2000) proposed six vital elements for tumor formation, Survival and Progression [1]. The six 'Hallmarks of Cancer' were sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, angiogenesis and activation of invasion and metastasis. Hanahan and Weinberg (2000) updated their findings in 2011 with further evidence describing the complexity of these hallmarks and the addition of further hallmarks, including modification of energy metabolism to fuel Cell growth and immuno surveillance evasion [2]. The tumor micro-environment is also a critical factor in the regulation of tumor growth and progression, with multiple stromal cell types creating a succession of supportive tumor micro-environments enabling invasion of normal tissue, and subsequent metastasis.

Recent successes have utilized these advances in understanding to create a strong biologic the rationale for drug development, primarily focusing on targets of a single 'Hall-

mark.' However, several challenges remain, not only in understanding the complex molecular pathways and networks, their interaction, and mechanisms of resistance but also in the drug development process through the early incorporation of biomarkers to create rational drug development strategies. Challenges also lie in defining robust criteria to appropriately select patients for novel therapies Effective trial design with integration of patient enrichment strategies are paramount to streamlining drug development and delivering timely information to guide the progress of drugs along the pipelines. From hypothesis to proof of concept. Historically, the emphasis on drug improvement has centered on evidence-based medicine in large trials of unselected affected populations, with the benchmark endpoint for new pills is the standard survival or other intermediate endpoint. This 'one size suits all' paradigm no longer continually bear in mind intra- and interpatient tumor heterogeneity, usually main to big-scale failure charges of multinational segment-III trials. Incorporating measures of pathway interest and tumor efficacy into the early phase trials may help prevent failure in the later phases of drug development.

Early validation of pharmacodynamics assays to degree target blockade and investigate optimum dose variety and Dosing is vital. Organizing 'proof-of-idea' can then correlate with anti-tumor activity in a selected patient population with confirmed predictive and intermediate [3]. For example, in patients with non-small cell lung cancer (NSCLC), the correlation of epidermal growth factor receptor (EGFR) mutations with response to the EGFR inhibitors gefitinib or erlotinib was the simplest after several poor trials. Although phase-II data in the 2D-line placement in patients with NSCLC are encouraging when taken to a segment-III trial in an unselected organization of patients with refractory ailments, gefitinib failed to show a gain in both average survival and time-to-remedy failure when compared to placebo. In this context, it was only that retrospective analyses ought to assist in picking out a subpopulation making the most of treatment inclusive of being a girl, a by no means-smoker, and of an Asian foundation. In addition, erlotinib demonstrated development-loose and typical survival benefits, both in the 2nd-line putting and as maintenance therapy in patients with stable sickness after first-line chemotherapy [4]. However, the incremental benefits in those unselected affected person populations have been small, measured in weeks for progression-free survival and 1-2 months for ordinary survival. in the long run, it was the choice of patients based on EGFR mutation popularity that tested a marked development in reaction costs and survival in segment-III trials evaluating chemotherapy and gefitinib in addition to chemotherapy and erlotinib in the first-line setting [5]. We conducted similar studies in patients with advanced colorectal cancer (CRC) treated with the monoclonal antibody cetuximab. First, cetuximab was administered to patients with EGFR overexpression, assessed using immunohistochemistry (IHC) on formalin-constant paraffin-embedded (FFPE) tumor specimens [6].

It was best later that the significance of Kirsten rat sarcoma-2 virus oncogene (KRAS) the mutation turned into tested; and this, in aggregate with an expanded knowledge of the complex EGFR downstream signaling cascade changed into step one in figuring out a predictive biomarker for EGFR-targeted cures in patients with ACRC. Several studies identified that sufferers with KRAS mutation did now not respond to EGFR-targeted treatments, whereas patients who had wild-type (wt) KRAS tumors had response rates of over 50%. More recently, it has been validated that in reality, not all KRAS mutations are created equal. even though the presence of most of the people with KRAS mutations avoid response to the EGFR inhibitors in ACRC, different KRAS mutations, mainly in codon 13, might also expect a response much like that verified in wt KRAS tumors [7]. Those are only some examples that show how the improved knowledge of tumor biology helps a speculation-pushed method to the invention of compounds to probably generate more selective inhibition of key signaling proteins, pathways, and networks. In this context, one of the toughest responsibilities is the identification of the proper goal and, more importantly, whether this target is 'druggable'. for instance, although we know that RAS mutations are an early factor of tumorigenesis and are identified in about 30% of human cancers that try to achieve the goal of RAS but were unsuccessful; to date, complex molecular structures constrain binding to the active site or pocket [8]. In contrast, selective inhibition of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in patients with BRAF V600 mutant melanoma is associated with a dramatic improvement in response rates and survival. The strong biologic rationale behind this approach was established through the identification of the importance of the mitogen-activated protein kinase (MAPK) pathway in this disease.

1.1 Biomarker Development

Predictive and prognostic biomarkers are increasingly important in tailoring the treatment decisions of individual patients. These markers are objectively measured to evaluate pathological processes or pharmacological responses to therapeutic intervention, and can be any kind of molecule, substance, or genetic marker which is traceable [9]. Predictive biomarkers provide information on response to treatment, whereas Prognostic biomarkers provide information about outcomes independent of treatment effects. Historically, biomarkers have often been developed in retrospective analyses and were only in some cases, prospectively applied. The retrospective approach was often criticized for being slow and difficult in practice, as well as raising concerns regarding heterogeneous Sample Collection and Validity. There are increasing efforts to incorporate new biomarker strategies into the earliest stages of clinical trial design, whether these are mutational analyses, clinical, or imaging measures, so that information can be gathered early and continually revisited during and after trial completion to inform the clinical development process.

As witnessed with several targeted agents, such as trastuzumab in human epidermal growth factor receptor-2 (HER2) positive breast cancer, the prospective analysis of HER2 as a predictive biomarker in clinical trials resulted in higher re-

sponse rates and increased survival in this selected patient population, both in the metastatic and adjuvant setting. This selective approach not only led to better outcomes for this subgroup, but ultimately to shorter and streamlined regulatory approval timelines. The use of trastuzumab in an unselected breast cancer population would undoubtedly masked its true efficacy and potentially curtailed its development. Importantly this selective biomarker approach became a good example of what challenges Researchers face challenges when developing accurate, functional, and standardized biomarkers.assays.

HER2 gene amplification was first observed to be a potential biomarker in breast cancer when its presence in 25% of axillary lymph-node-positive breast cancers was correlated with a worse prognosis. Additional studies confirmed that HER2 protein overexpression was also a poor prognostic marker in breast cancer, correlating with decreased relapse-free, and overall survival. The trastuzumab clinical trials were initially designed using HER2 over-expression measured by IHC with a centralized sponsor-developed assay, which was particularly important as there was no standardized assay at that time. As the testing of HER2 was expanded from central to local laboratories,With the incorporation of fluorescence in-situ hybridization (FISH) in addition to IHC, there were describes the correlation and regulation of these assays.

Although the results of the five adjuvant trastuzumab trials in HER2-positive early stage breast cancer clearly showed a significant clinical benefit in both progression-free and overall survival, the testing algorithms for HER2 were not consistent across these trials.HER2 testing included either IHC supported by FISH testing for intermediate IHC result (IHC2+), or reliance on FISH testing alone to assess gene amplification ratios. Concern was generated at the lack of accuracy and validation of HER2 testing in some instances, as several assays were in use, including both validated assays and so-called "home brew" assays developed in the local pathology laboratories. Sub-studies from two of the adjuvant trials demonstrated that approximately 20% of HER2 assays performed at the primary treatment sites were incorrectly compared to re-evaluation in a high-volume central laboratory. Furthermore, the sensitivity of IHC itself is a concern. For example, one study demonstrated that commercially available US Food and Drug Administration (FDA)-approved IHC methods were significantly less accurate than FISH at correctly characterizing tumors with a known HER2 status. Depending on the IHC method and use of HER2 antibody, correlation with FISH positivity ranged between 67-83%, with greater susceptibility to interobserver variation [10]. Clearly, in the case of IHC testing, several contributing factors may further impact sensitivity and specificity, including initial sample processing, time to any type of fixation, analytic variables of assay validation, equipment calibration, and use of standardized laboratory procedures, training of staff, test reagents, use of standardized control materials, and use of Automated Laboratory Methods.

Slamon et al. (1989) demonstrated that a proportion of breast cancers known to have gene amplification and over-expression of HER2 lose membrane staining after paraffin embedding and negative on IHC assessment. Loss of antigenicity resulting in a potential False-negative IHC results can be affected by the poor standardization of fixative methods. To overcome this lack of concordance in HER2 testing, which can so markedly impact on patients' prognosis and survival, an American Society of Clinical Oncology (ASCO) panel developed guidelines for improving the accuracy of HER2 testing. These recommendations covered over 30 aspects of testing and requirements including the HER2 the testing algorithm, optimal FISH and IHC testing and interpretation, tissue handling, internal validation and quality assurance procedures, optimal external proficiency, laboratory accreditation and regulatory requirements, statistical requirements for assay validation and International External Quality Assessment Initiatives. Despite these guidelines, there were concerns that IHC assessment still lacked sufficient sensitivity to be used alone to decide on HER2 status though this remains the standard initial assessment in most laboratories [11].

In 2010, the addition of trastuzumab to first-line chemotherapy in HER2-positive advanced gastric cancer demonstrated a survival benefit [12]. Similar to breast cancer, approximately 20-30% of gastric and gastro-oesophageal junction (GOJ) cancers show HER2 overexpression, but the testing criteria for gastric specimens differ significantly [13]. This is related to the increased frequency of heterogeneity of HER2 positivity in gastric cancer compared with breast cancer, as well as variations in membrane staining and several stained cells are necessary to diagnose a positive case. In addition, there is also a less stringent correlation between HER2 amplification and protein over-expression with more than 20% of cases carrying HER2 amplification, often at a low level, without HER2 expression. Clinically, in this group of patients, there is no apparent benefit from adding trastuzumab for chemotherapy. Similarly, Hohmann et al. demonstrated concordance between FISH and IHC of 93%, with 7% of specimens demonstrating FISH positivity with negative or equivocal IHC staining [14]. Discordant findings have also been demonstrated with HER2 testing on surgical specimens compared with biopsy alone, with more than 10% of cases showing discrepant results. As a result, if only gastric or GOJ cancer biopsy samples are available for HER2 testing, current guidelines recommend sampling at least 6 different areas of the tumor for HER2 analysis. New IHC scoring criteria have also been developed for gastric and GOJ cancers and were validated by Hohmann et al. (2008b), further demonstrating that the analysis of HER2 based on the breast cancer guidelines may lead to false negative reporting in the gastric cancer specimens [15].

This example demonstrates that although an assay may have progressed through thorough validation and review processes in one cancer sub-type, its use cannot be assumed for other malignancies and re-validation need to be incorporated into early-phase trials, particularly when the drug is readily available, and may otherwise rapidly proceed to clinical practice. Furthermore, when several IHC assays exist, it is of

the utmost importance that laboratories validated internal IHC and FISH procedures according to international guidelines. In this context, it is paramount that biomarker development is orchestrated collaboratively in large multi-institutional networks. The integration of biomarkers early in drug development and correlation with clinical observations can generate early signals of unexpected efficacy or resistance that can then be used to change the direction of development of a particular drugs and enhance outcomes. Furthermore, new health information technologies (HIT) are a pivotal part of biomarker development and need to be linked into routine practice to support the large-scale Information on tumor biology and clinical data. The use of HIT will also support the integration of a variety of data sets including gene expression profiles, metabolic, Immuno histochemical Profiles and Clinical Outcome Data. The development of next-generation sequencing, functional genomic screening, and transcriptional analysis offers detailed insights into not only the DNA sequence but also mRNA profiles, protein structure, and metabolic pathways. The enormity of the information that is available needs parallel information technologies to interpret and link these findings to the regulated networks. The ultimate application of these technologies involves the modeling of interacting pathways to make phenotypic predictions and develop complete system models to advance personalized drug development. The incorporation of molecular biology and information technology can thus maximize the interpretation, application, and targeting of these complex oncological systems. In this context, bioinformatic has evolved to combine sequence matching and pattern discovery with the modeling of dynamic biological systems to enhance

1.2 Development of New Rationally Design Targeted Therapies

Developments of new rationally designed targeted therapies several recent phase-I trials of molecularly targeted agents have demonstrated remarkable progress when patients were selected based on their molecular profile and subsequently cells treated with an agent directed against a specific target. The shift from 'one size fits all too molecularly defined subpopulation has been particularly successful treatment of patients with advanced BRAF mutant cutaneous melanoma. Two pivotal phase-I trials showed encouraging response rates and improved survival rates with the selective BRAF inhibitors, vemurafenib (PLX4032) and GSK 2118436, in a disease is notoriously resistant to standard chemo therapies. Another trial in patients with NSCLC who were carriers of the EML4-ALK fusion protein showed remarkable response rates with New ALK inhibitor, Crizotinib. The successful development of such agents is, of course,complex but can be simplistically considered as having three key components: the right target (strong biologic rationale, druggable), the right drug (selective, right formulation), tolerable side-effect profile), and the right biomarker (reproducible and validated) (Figure 1)



Figure. 1: Key Components of Oncology Drug Development

This paradigm can be further evidenced by the success of imatinib and CAL-101 in hematological malignancies and reflects the limitations that have impacted the use of other agents, such as sorafenib in melanoma or bevacizumab in breast cancer, and other malignancies.

Sorafenib is an oral multi-kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth element receptor (PDGFR), and Raf-1. Although it was first developed as an RAF inhibitor, sorafenib has proven to be the best treatment. Slight IC50s for all three RAF isoforms and additionally had inhibitory outcomes on several other Receptor tyrosine kinases include VEGFR2, VEGFR3, PDGFRβ, cKIT, and FLT3. Sorafenib Has proven substantial improvements each in medical advantage charge and survival in renal Cell carcinoma (RCC) and hepatocellular carcinoma (HCC) [16]. Correlative markers had been integrated into those trials, which include phosphorylated ERK (Perk) immuno staining and soluble c-package, VEGFR2, VEGFR3, and VEGF ranges. As yet however, there are no established biomarkers to predict the goal-affected population.

Notwithstanding a great biologic rationale to aid its use in melanoma and promising early sections Sorafenib failed to expose a scientific gain in phase II-III trials [17, 18]. Not like the early sectional trials for the selective BRAF inhibitors, Sufferers were no longer selected for BRAF mutations, one of the key drivers in cutaneous melanoma, nor were the pharmacodynamics markers from the early phase trials translated into the design of phase-III trials could have prevented the failure of a melanoma drug development program if phase-II data had been critically reviewed and early 'go or no-go' decisions had been integrated into the decision-making process for the phase-III trials. In contrast, the development of bevacizumab, a drug targeting the 'angiogenic switch' and tumor-associated neovascularization, was highly anticipated. Early preclinical evidence indicated that bevacizumab not only inhibited the formation of new blood vessels but also caused regression of existing micro vessels and sta-

bilized mature vasculature to improve drug delivery. Clinical benefits have been demonstrated in advanced colorectal cancer when used in combination with chemotherapy. However, despite promising data, identifying a predictive biomarker remains elusive, leading to controversy over its widespread use owing to associated costs and toxicity concerns. The lack of proven and validated biomarkers may have contributed to the approval of the FDA for metastatic breast cancer.

Notably, the successful development of selective BRAF inhibitors for BRAF V600 mutation-positive advanced cutaneous melanoma was based on a strong biological rationale and benefited from the validation of an associated predictive biomarker. Over 80% of primary melanomas show aberrant activation of the MAPK pathway due to abnormalities in the RIFF-RAFF K-ERK pathway, with BRAF mutations being among the most studied. Early-phase trials with selective BRAF inhibitors have demonstrated significantly higher response rates and improved survival compared to standard chemotherapy. Identification of the BRAF mutation as the right target enabled the development of selective BRAF inhibitors, the efficacy of which could be predicted by the presence of this biomarker.

Similarly, activating mutations or translocations of the ALK gene have been found in several types of cancer, with the EML4-ALK fusion gene being evident in 2-7% of all NSCLC cases. Crizotinib, a selective inhibitor of ALK and MET tyrosine kinases, showed unprecedented response rates and clinical benefits in a phase I trial of advanced NSCLC patients with ALK rearrangements. Molecular analysis of tumor samples using FISH, IHC, and RT-PCR was incorporated into the study, and FISH positivity for ALK rearrangement correlated with aberrant expression of ALK protein on IHC, although not all patients had positive EML4-ALK results.

Overall, incorporating early biomarker validation and data reviews in clinical trials can significantly impact the success of drug development programs and improve patient outcomes. On the RT-PCR assay. The use of prospective tumor genotyping not only potentiated their development of diagnostic approaches for these patients but has also streamlined rapid

Development of Crizotinib drugs Remarkably, there were only three years between target the identification, initiation of the phase-I trial, and enrolment in the phase-III registration trial, and this stands in contrast to more than ten years from the initial unsuccessful trials of EGFR inhibitors in non-genotypes, unselected patients to the phase–III trials that demonstrated Benefits of EGFR inhibitors in EGFR-targeted tumors. Again, there is strong supporting evidence for 'the right target' and 'the right drug' in this setting, while development of 'the right biomarker' has been incorporated into the phase-I trial to assist in overcoming the complexities inherent in new assay validation.

In hematological malignancies, the development of the phosphatidylinositol 3-kinase (PI3K) inhibitor, CAL-101, has shown encouraging results in advanced non-Hodgkin lymphoma (NHL), mantle cell lymphoma, and chronic lymphocytic leukemia (CLL) [19]. CAL-101 is a selective inhibitor of the PI3K p110 δ isoform that is primarily expressed on cells of hematopoietic origin and has a key role in B cell maturation and function. Through inhibition of PI3K signaling, CAL-101 can induce apoptosis of primary CLL and acute myelogenous leukemia (AML) cells and a range of other leukemia, and lymphoma cell lines. In phase-I–studies, CAL-101 has demonstrated durable clinical responses in several hematological malignancies, including NHL [20]. Reduction in phosphorylated AKT (pAKT) as a marker of PI3K activation provides 'proof-of-mechanism' for this agent and later phase trials are underway in B cell malignancies with markers along the PI3Kδ pathway acting as predictive biomarkers.

These recent 'proof-of-concept' studies were the first of their kind where molecular profiles were used for the selection of 'new in class' compounds and demonstrate that when patients are appropriately selected, convincing benefit can be realized in the earliest of trials, setting the stage for rapid drug approval. This phase-I experience has convinced investigators that tumor profiling and patient selection will become a routine part of cancer drug development.

1.3 Challenges in Drug Development

Mechanisms of resistance:- Despite the advances in parallel drug and biomarker development in early clinical trials, one of the major challenges remaining is the understanding of mechanisms that cause primary and acquired or secondary resistances, respectively. Primary resistance is characterized by a lack of efficacy of an agent from treatment initiation, whereas acquired resistance develops after an initial responses to some degree over time.

As evidenced by all currently approved molecularly targeted agents, initial treatment may yield response rates far higher than standard chemotherapy with impressive disease control, However, resistance and tumor progression inevitably occur. Importantly, understanding the mechanisms of resistance can lead to rationally designed drug combinations incorporating Targeted agents, antibodies, or cytotoxic agents this approach should include continuous analysis of tumor material via biopsies on disease progression or surrogate markers such as Circulating tumor cells (CTCs) or circulating free DNA (cfDNA). In this context, cancer treatment could follow strategies as witnessed by the treatment of tuberculosis with quadruple combination regimens or human immunodeficiency virus (HIV) with highly Active antiretroviral therapy (HAART). Similarly, cancer drugs will be used in parallel or sequentially to block the different driver pathways and networks simultaneously.

Although several mechanisms of resistance are several mechanisms of resistance a rare particular to molecularly targeted agents and are intrinsic to the pathway they inhibit, there are other mechanisms that are common to both cytotoxic chemotherapy and molecularly targeted agents

falling into three main categories: decreased uptake, such as occurs with water-soluble drugs like the folate antagonists; impaired capacity of cytotoxic drugs to induce cell kill via a combination of altered cell cycle checkpoints, increased or altered drug targets, and repair of DNA damage, inhibition of apoptosis, or increased drug efflux [21].

The presence of efflux pumps is one of the nicely defined mechanisms of resistance and is concept is not unusual for cytotoxic chemotherapy and molecularly targeted retailers. P-glycoprotein (P-pg), otherwise referred to as the multi-drug transporter, is a power-dependent efflux pump that has been recognized as a chief mechanism of multi-drug resistance (MDR) in cultured cancer cells. It by far the product of the MDR1 gene in people and is one member of a massive family of ATP-dependent transporters known as the ATP-binding cassettes (ABC family). P-pg is widely expressed in lots of human cancers which include cancers of the gastrointestinal tract, hematopoietic gadget, genitourinary machine, and youth cancers. P-pg can discover and bind a massive kind of hydrophobic natural-product capsules as they enter the plasma membrane along with chemotherapeutic sellers such as doxorubicin, vinblastine, and paclitaxel, as well as antiarrhythmic, antihistamines and the HIV protease inhibitors [22]. Improved drug efflux changed into, to begin with, the notion being a big mechanism of resistance for the tyrosine kinase inhibitor imatinib in patients with CML. But, it is not completely understood how lots affect this resistance.

The mechanism uses molecularly centered tablets as the top source of resistance. Any other applicable mechanism of resistance that has been illustrated in several cancers includes the disruption of interacting proteins and receptors at the plasma membrane degree impacting receptor binding and next-drug efficacy. as an instance, EGFR is a membrane-bound receptor whose signaling entails a complicated pathway of ligand binding, receptor homo- and heterodimerization with ERBB2 and different own family participants, followed via internalization and recycling of the ligand-sure receptor. Considerable EGF-established signaling can also arise at some stage in the system of internalization and alterations in EGFR trafficking have been related to cell responses. Evaluation of EGFR trafficking in resistant lung most cancers cellular traces validated expanded internalization of EGFR in comparison to parental drug-sensitive cells, which apparently may be conquered with the aid of the action of irreversible EGFR inhibitors. In addition to breast cancer, one of the proposed mechanisms of resistance to trastuzumab entails membrane-associated glycoprotein mucin-4 (MUC4) which can also block the inhibitory moves of trastuzumab by immediately binding with HER2 and preventing interaction between the drug and the molecular target. Primary or secondary mutations and aberrations at the extent, up or downstream of the goal are also frequently studied mechanisms of resistance to molecularly focused agents. For instance, number one resistance to the EGFR-focused dealers, Gefitinib and erlotinib, has been associated with the presence of a KRAS mutation in 20-30% of NSCLC patients, or via an insertion mutation in exon 20 of EGFR, which represents fewer than five% of all acknowledged mutations in EGFR [23].

Secondary resistance to the EGFR inhibitors after a preliminary response is mediated via the T790M mutation in 50-fifty nine% of patients, characterized by way of the substitution of methionine for threonine at function 790 (T790M) in EGFR. In this example, organic knowledge of number one and secondary resistance allows for the development of rationally designed drugs. Pre-scientific proof demonstrated that an irreversible inhibitor of EGFR, together with neratinib (HKI-272), should overcome resistance precipitated through T790M-mutant EGFR and such dealers are currently in clinical improvement.

Latest advances within the treatment of cancer have in addition assisted with the know-how of the complexity of resistance mechanisms. For example, although secondary BRAF mutations have now not been diagnosed as a reason for BRAF inhibitor resistance, mutations elsewhere along the MAPK pathway are implicated in secondary NRAS and MEK mutations.signaling pathway [24]. modifications in signaling upstream of a target pathway in addition to passing signaling alongside change pathways have been confirmed as the mechanisms of resistance (Parent 3). In this context the insulin-like growth thing 1 receptor (IGF1R) which indicators upstream of the PI3K-AKT-mTOR and MAPK pathways have been discovered to contribute to resistance in several malignancies. As an example, the interest in trastuzumab turned impaired in breast most cancers cells that over-expressed each HER2 and IGF1R, but its hobby may be restored whilst IGF1R activation becomes blocked. Furthermore, in vitro, fashions have demonstrated that IGF1R physically interacts with and induces phosphorylation of HER2 in trastuzumab-resistant cells, but not in trastuzumab-sensitive cells, with subsequent accelerated signaling via the PI3K-AKT-mTOR and MAPK pathways. again, inhibition of IGF1R signaling either through antibody blockade or tyrosine kinase inhibition restored trastuzumab sensitivity, demonstrating every other potential healing mechanism to triumph over secondary resistance to trastuzumab. Similar findings had been also obtrusive in BRAF V600E cancer cellular strains immune to BRAF inhibition, offering early proof for the A mixture of IGF1R and MEK inhibition.

Some of the other preclinical research have also tested aberrant activation of the PI3KAKT pathway at different levels that contribute to both primary and secondary resistance in BRAF mutant cell traces. Just because the aggregate of IGF1R inhibition with MEK inhibition is being investigated to triumph over resistance mediated along the IGF1R and MAPK pathways, there can be a biological purpose for the mixture of PI3K and MEK inhibitors. In such cases, phosphorylated AKT can also act as a marker of hobby of the PI3K-AKT-mTOR pathway and for that reason, may be used as a biomarker to pick when the aggregate of PI3K inhibitors and BRAF/MEK inhibitors is suitable to block both the PI3K and MAPK pathways respectively PTEN loss (PTEN-) and the next lack of inhibition on the PI3K-AKT-mTOR pathway have also been

shown to confer resistance to BRAF inhibition. Paraiso et al. (2011) showed that during mobile strains with PTEN loss as compared to cellular traces with normal PTEN, BRAF inhibition with vemurafenib was associated with improved AKT signaling and reduced apoptosis. Dual treatment of PTEN-cell strains with each vemurafenib and a PI3K inhibitor could then restore extended tiers of apoptosis.

Exemplified by using preclinical and clinical examples in melanoma, signaling through the PI3K-AKTmTOR pathway mediates an important MAPK-pathway unbiased mechanism of resistance in an expansion of cancers and demonstrates a complex crosstalk between those pathways [25]. Dimension of phosphorylated ERK and phosphorylated AKT to decide pathway activity may therefore assist in manual therapeutic choices and mixtures of selective BRAF, MEK, or PI3K/AKT inhibitors. Accordingly, knowledge of secondary resistance mechanisms will an increasing number of have an effect on choice-making procedures for similar drug development and rational drug combinations. Even though mechanisms of secondary resistance are properly described for numerous newly centered marketers, demanding situations remain, especially with anti-angiogenic or multi-targeted retailers together with bevacizumab, sunitinib, and sorafenib. The complexity of resistance mechanisms to antiangiogenic therapy reflects the difficulty in developing anti-angiogenic dealers in parallel by using the corresponding biomarkers. Thus far, the main resistance mechanisms of anti-angiogenic sellers have been proposed. First of all, evasive resistance with a model to bypass particular angiogenic blockade, and the second is intrinsic or present-present indifference. Evasion of antiangiogenic therapy might also occur thru the up-regulation of opportunity seasoned-angiogenic s circuits or via a number of signaling alterations within the micro-environment, together with the recruitment of vascular progenitor cells and seasoned-angiogenic monocytes from the bone marrow, accelerated and tight pericyte insurance defensive tumor blood vessels, and the extended ability for invasion without angiogenesis.

Change seasoned-angiogenic signals which have been implicated in preclinical research consist of fibroblast increase component (FGF)-1 and -2, ephrins A1 and A2, and angiopoietin-1. To establish the importance of those up-regulated genes, preclinical studies used the combination of FGF signaling suppression with VEGFR inhibitors and established that the aggregate of these retailers attenuated re-vascularisation and slowed tumor growth [26]. Those findings were also visible clinically in patients with glioblastoma handled with the VEGFR inhibitor cediranib [27]. After the initial reaction, peripheral blood stages of FGF2 accelerated when sufferers improved, suggesting that signaling through FGF assists in restoring angiogenesis. Accelerated ranges of seasoned-angiogenic elements which include VEGF and placental increase component (PGF) had been previously proposed as predictive biomarkers for tumor response [28]. But there may be also proof that the expression of seasoned-angiogenic increase factors along with FGF, PDGF, and others increase in advanced ranges of metastatic breast cancers, resulting in alternate pathway signaling. Hence, there's uncertainty concerning the significance of those elements; whether or not the presence of seasoned angiogenic elements in peripheral blood are in reality markers of response or resistance, or neither. knowledge of the complicated regulatory networks, the interplay of seasoned- and antiangiogenic elements, and contributing components of the micro-surroundings illustrates the problems to date in goal and biomarker development, as well as the capacity mechanisms with the aid of which anti-angiogenic remedy can be optimized.

Malignancy and Drug	Target	Biomarker	Mechanisms of Resistance Under investigation
Breast cancer			
Tamoxifen	Estrogen receptor	ER/PR status on IHC	Loss of ER expression Epigenetic changes in ER gene Increased drug metabolism ER/HER2 cross-talk PI3K-AKT pathway activation Alterations in co-regulatory proteins (Ring et al., 2004)
Trastuzumab	HER2 receptor	HER2 expression on IHC and/or FISH	MUC4 binding to HER2 (Nagy et al.; 2005) HER2 & IGF1R crosstalk (Lu et al., 2001) PI3K-AKT pathway signalling and PTEN loss
Bevacizumab*	VEGF-A and VEGFR2	Nil currently validated Preliminary evidence on clinical, biochemical and radiological assessments	Alternate pro-angiogenic signalling circuits (eg. FGF) Bone marrow derived vascular progenitor cells & pro-angiogenic monocytes Increased pericyte coverage (Bergers & Hanahan, 2008)
Melanoma			
Sorafenib	RAF, VEGFR, PDGFRβ, cKIT, FLT3	Nil currently validated	Alternate pro-angiogenic signalling, PDGFR mt Glucose-regulated protein 78 (Chiou et al., 2010)
Vemurafenib/ GSK 2118436	BRAF V600E/K mt	BRAF mt status	Upstream: IGF1R, PDGF upregulation, NRAS mt (Nazarian et al., 2010; Villanueva et al., 2010)) Target level: BRAF amplification, CRAF activity (Corcoran et al., 2011; Montagut et al., 2008) Downstream: MEK mt (Corcoran et al., 2011) Alternate pathway signalling: PI3K-AKT-mTOR activation
Lung Cancer			
Erlotinib/ Gefitinib	EGFR	EGFR mt status	KRAS mt EGFR T790M mt (Pao et al., 2005) EGFR insertion mt in exon 20 (Hammerman et al., 2009) EGFR trafficking (Kwak et al., 2005)

Malignancy and Drug	Target	Biomarker	Mechanisms of Resistance Under investigation
Crizotinib	ALK and MET tyrosine kinases	EML4-ALK expression on IHC, ISH and/or RT PCR	EML4-ALK with C1156Y mt EML4-ALK with L1196M mt (Choi et al., 2010)
Colorectal Cancer			
Cetuximab	EGFR	KRAS mt (codon 12)	KRAS codon 61/146 mt BRAF mt (Loupakis et al., 2009) PIK3CA mt (Sartore-Bianchi et al., 2009) PTEN loss of expression (Frattini et al., 2007)
Haematologic malignancies			
Imatinib	BCR-ABL tyrosine kinase, cKIT	BCR-ABL mRNA on PCR (peripheral blood) Cytogenetic analysis on bone marrow aspirate	Drug efflux (Mahon et al., 2003) ATP binding site mt (Branford et al., 2003) KIT mutation (in GIST) (Tamborini et al.; 2004)
CAL-101	PI3K p110δ	pAkt and markers along the PI3K δ pathway	

Figure. 2: Selected Examples of Molecularly Targeted Therapies and Mechanisms of Drug Resistance

*Evidence for bevacizumab also applies to colorectal cancer, NSCLC, renal cell carcinoma and other Malignancies
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor 2;

- IHC: immunohistochemistry; mt: mutation
- IGF1R: insulin growth factor-1 receptor; PDGF: platelet

derived growth factor
- EGFR: epidermal growth factor receptor; PI3K: phosphatidylinositol-3kinase
- PTEN: phosphatase and tensin homologue

The breakthroughs and dilemmas of recurrent tumor biopsies even though many mechanisms of resistance can be recognized via research of cellular traces and xenograft models, it is regularly via correlation with sufferers' tumor specimens that legitimate conclusions can be drawn approximately the importance of these resistance mechanisms inside the scientific putting. To this end, get entry to longitudinal tumor biopsies and evaluation of those in 'actual time' might also change the treatment paradigm for sufferers. The want for longitudinal tumor biopsies is evidenced at some degrees. Firstly, it assists in know-how and mapping the complicated molecular networks, verbal exchange with the micro-surroundings, angiogenesis, and other 'hallmarks'. As technologies in tumor analysis improve, as an example with high throughput genetic sequencing and unraveling the most cancers genome, findings on the pre-clinical level may be investigated and explored clinically and adjustments in tissue can be correlated with healing response.

Secondly, there are more than one variables that can affect the accuracy of mutational analysis on tumor tissue, no longer least that the tumor itself can develop new mutations and aberrations that drive tumorigenesis. Research of concordance or lack thereof, among archival primary tissue and biopsies of metastatic ailment, have demonstrated this in breast, colorectal, and other malignancies. Analyses of HER2 over-expression in primary breast cancers and metastatic websites exhibit that up to 12% of sufferers might also have HER2 terrible number one breast cancer with HER2 positivity at the metastatic websites, and the next capability therapeutic benefit from trastuzumab. Conversely, up to 30% of tumors should transfer from HER2 positive repute on primary tissue to HER2 bad fame on metastatic tissue, again significantly impacting future treatment selections.

In patients with advanced colorectal cancers, retrospective analyses have assessed the concordance of KRAS mutation popularity and other changes along the MAPK and PI3KAKT-mTOR pathways among number one tumors and metastatic web sites. Loupakis et al. (2008) assessed PTEN fame which regulates the PI3K-AKT-mTOR pathway, and verified that PTEN loss passed off in 37% of tumors with a related lack of response to cetuximab and irinotecan. The suggested PTEN concordance among primary tumors and metastases turned into 60% in comparison to 95% for KRAS mutations. In those sufferers who had been KRAS wild-type and PTEN high-quality on metastases, there was proof of improved RR and PFS indicates the importance of pathway profiling to be expecting a medical response. Those examples underline the significance of tumor assessment not handiest for sufferers who expand metastatic disorder after resection of primary cancer, but additionally for sufferers with revolutionary disease on remedy. know-how of the 'using' pathway, receptor, or, community before treatment initiation, especially with new molecularly centered marketers, will come to be preferred of care for several new treatments and guide us within the choice making algorithm even in advanced ranges of ailment. This can be similarly evidenced through a current study in a cohort of closely pre-handled segment-I patients who were tested for aberrations within the MAPK and PI3K-AKT-mTOR pathways and then handled with pills focused on these pathways. Impressively, those sufferers with molecular changes dealt with centered remedy had a response rate of 29% (entire reaction or partial response) as compared to eight% inside the organization without alterations. The proportion of patients with stable sickness past 6 months and the median survival had been also higher in this affected person group.

Importantly the recent early section-I melanoma studies with selective BRAF inhibitors have integrated tumor biopsies at baseline, on-remedy, and on-development biopsies to analyze the changes in pathway signaling.

The tumor analyses blanketed no longer only immuno histochemical staining, but also Sequenom Mass Array of over four hundred gene mutations, including BRAF, RAS, PIK3CA, AKT1/2, CDK4 and others. Following this technique, sufferers were selected for the BRAF mutation at baseline and monitored during remedy with the size of phosphorylated MEK and ERK tiers to confirm target inhibition. On development, several potentially large genetic alterations have been recognized, together with NRAS and MEK1 mutations indicating persevering with MAP-pathway signaling. Further PTEN loss and an increase in pAKT have been determined, demonstrating activation of the PI3K-AKT-mTOR pathway as a likely alternate signaling pathway. The danger-advantage of serial tumor biopsies wishes to be well balanced and risks and hazards acknowledged. As instance, in some cancers like NSCLC, get entry to tumor tissue is limited using the website of sickness with an expanded potential chance of pneumothorax, bleeding, and other headaches secondary to a lung biopsy. Tissue biopsies also run the danger of sampling error, in element from tumour heterogeneity. As discussed with HER2 trying out in gastric most cancers, multiple biopsies can be required to minimize the hazard of missing the alteration of interest, in this example HER2 amplification and protein over-expression. In addition, sample management, fixation, validation of assays, inter-observer variability, and evaluation, all contribute to the accuracy of the very last result on which medical decisions are made. Ultimately, new technology additionally wants to be tested before recurring creation into medical care. even though the capability to sequence the genome and carry out genetic profiling on patients' tumors dramatically escalates the facts to be had on a man or woman patient, the significance of these facts remains, as yet, frequently unknown. The presence of a mutation no longer decides its significance in tumorigenesis, such that inhibition of a given mutation will not correlate with medical gain if the mutation was an incidental finding rather than an oncogenic mutation.

The role of circulating tumor cells and circulating free DNA: -

Detection of circulating tumour cells (CTCs), and circulating free DNA (cfDNA) in peripheral blood specimens potentially presents an easily accessible 'liquid biopsy' without the risk of tumor biopsies and further, may not only provide a predictive biomarker for a given treatment but also contain information on molecular aberrations and changes in pathway signaling while on treatment. There is increasing evidence that CTCs can be used as a surrogate endpoint for progression-free and overall survival and thus, allow an earlier assessment of the clinical benefit of a particular agent to streamline drug development and regulatory approval. Such 'surrogate endpoints' may accelerate drug development as long as adequate and well-controlled clinical trials establish that the new drug has an effect on this surrogate, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, and that this surrogate endpoint can predict clinical benefit and survival [9].

The enumeration of CTCs and their utility as a prognostic and predictive biomarker has been best characterized in breast, colorectal, and prostate cancers with further evidence in other malignancies including melanoma and lung cancers. The most widely used and FDA-approved method for CTC enumeration and molecular characterization is the Cell Search system, which involves the immuno magnetic capture of CTCs using antibodies against the epithelial cell adhesion molecule (EpCAM), expressed on the cell surface of most epithelial malignancies. Additional cell identification includes the detection of pan-cytokeratin antibodies, DAPI nuclear staining (4, 6-diamidino-2-phenylindole staining to detect nucleated cells) and CD45 negative selection to demonstrate the detected cell is not a leucocyte. The presence of CTCs at baseline in metastatic breast cancer has not only been demonstrated to have prognostic significance but has also been shown to be the strongest predictor of overall survival when compared to age, hormone receptor status, HER2 status, and metastatic site. It also maintains its prognostic value independent of the line of treatment, site of recurrence and disease phenotype [29]. Preliminary studies in breast cancer suggest that CTC enumeration may even be superior to a radiological evaluation in predicting response to treatment and outcome. It may provide a more reproducible indication of disease status compared to current imaging methods, particularly given inter-reader variability in confirming radiological response which can vary by up to 15% compared to 1% variability for CTC counts [30]. In castrate-resistant prostate cancer, the presence of CTCs at baseline and lack of a decline during treatment is also indicative of poor response and survival. In multivariate analyses, CTC counts and PSA doubling time have been demonstrated as the only independent predictors for clinical outcome as compared to PSA level, Gleason Score, bone metastases, and age [31]. Additionally, there is now evidence that CTCs may be a potential surrogate biomarker in metastatic prostate cancer trials. The randomized, double blind phase III trial in metastatic prostate cancer, in which abiraterone was compared to a placebo, was the first of its kind to demonstrate the utility of CTCs in this setting. CTCs were measured at baseline and repeated at 4, 8, and 12 weeks post-treatment. Pre-treatment CTCs were strongly correlated with OS, as was a fall in CTC count on treatment. Particularly in the setting of castrate-resistant prostate cancer where there may be inter-observer variation regarding radiological progression, CTCs may provide an accurate and reproducible alternative. In patients with metastatic colorectal cancer, higher baseline CTC counts correlate with shorter PFS and OS. Again, conversion of an unfavorable baseline CTC count to a favorable count at 3-5 weeks after starting treatment is associated with longer PFS and OS compared with patients with counts at both time points. Baseline and follow-up unfavourable levels also remain strong predictors of PFS and OS after adjustment for clinically significant factors [32]. Recent evaluation of CTCs in patients with NSCLC has also suggested prognostic significance. CTCs in patients with NSCLC were found more commonly with stage IV (32%) compared to stage IIIB disease (7%) and in those patients with five or more CTCs detected, both PFS and OS were inferior. Particularly with the complexities in obtaining longitudinal tissue biopsies, further investigation of a prognostic 'liquid biopsy' and incorporation into early phase trials is of importance. In patients with advanced melanoma, recent studies have demonstrated a good correlation between CTC status and the tumor-node-metastasis stage, underlining the prognostic role of CTCs [33]. The predictive value of CTCs was so far limited by the fact that treatment options consisted of bio-chemo therapies with no effects on clinical outcomes. However, the presence of circulating melanoma cells after adjuvant treatment for stage III melanoma has been shown to correlate with inferior relapse-free and overall survival and may be a useful indicator of systemic sub clinical disease [34]. Isolation and molecular characterization of these cells, combined with analysis of cfDNA, presents an opportunity to obtain further information about the pathways driving tumorigenesis, invasion, and, metastasis. In addition to evaluating the role of CTCs in melanoma, one study found a good correlation between CTCs and cfDNA suggesting both markers may be a useful determinant of disease status and treatment effect. Patients with measurable CTC or cfDNA showed poorer disease outcomes even though compared with patients without these markers, and patients with both markers showed the most inferior disease outcome, e the treatment regimens were heterogeneous and consisted of bio-chemo therapies of limited clinical benefit [35].of these agents do not motive regular chemotherapy-triggered aspect consequences along with immuno suppression around which early section trial design has been primarily based. Therefore design of medical trials of novel agents has had to expand so that you can evaluate those sellers as it should be and efficiently [36].

Optimizing Trail Design : - In a trendy dose escalation segment I trial, cohorts of three to six patients are dealt with at pre-described dose degrees, dose-limiting toxicity (DLT) is observed and the maximum tolerated dose (MTD) is described as the dose level at which >33% of patients dealt with have experienced adult. Dose degrees are generally defined as the usage of amendment of the unique Fibonacci design (growing dose with the aid of fixed increments of a hundred%, 67%, 50%, and 40% followed with the aid of 33% for

all next levels) but slow attainment of the MTD and exposure to extensive numbers of sufferers to low doses were criticisms of this method [37]. An improved trial layout (Simon et al, 1997) is now an extensively standard opportunity to the Fibonacci dose-definition model and lots of trials now allow person sufferers to be dose escalated within a have a look at if secure to achieve this, aiming to minimize the ones being uncovered to in effective doses. therefore there are numerous combinations of version-based and rule-primarily based designs that permit flexibility of the recruitment shape in a trial and can be appropriately tailored to the agent under attention [38-40].The appropriateness of the number one endpoint of the most tolerated dose (MTD) has been challenged for some of those retailers and consideration has been given alternatively to the idea of most excellent organic dose (OBD). Centered organic retailers are extra usually cytostatic instead of cytotoxic, therefore other endpoints have to be taken into consideration while evaluating remedy efficacy along with novel radiographic assessment and immunotherapy assessment.

There has also been an increasing cognizance that patients want to be correctly decided on for sure marketers based on tumor biology and molecular characteristics. The question is whether or not the affected person's choice should take location at the outset of drug improvement, as a centered method that's then diversified; or whether a broader recruitment approach ought to be successful, to begin with, followed using trying out within a focused populace. There's consequently an important need to integrate and validate novel biomarkers into drug improvement from the earliest tiers of evaluation, incorporating tumor and non-tumour tissue samples to use those biomarkers appropriately and manual patient choice. Usual, within the technology of development of molecularly targeted sellers, correctly designed speculation-trying out trials must be conducted. Sufferers should be decided on rationally in line with tumor biology and molecular characteristics and especially, an element of flexibility ought to be allowed within the trial design to allow response to unexpected findings, whether or not that be toxicity or efficacy [41-45].

2. Research Method

The research approach used in this observation is possibly to contain a scientific literate valuation date or a meta-analysis of existing research papers, scientific trials, and studies associated with oncology drug improvement strategies within the era of personalized medicinal drugs. The researchers may also have hired numerous databases like PubMed, Scopus, or Net of Science to gather applicable articles. The chosen research ought to encompass a huge variety of strategies for personalized medication, consisting of genomic profiling, biomarker-pushed treatments, focused treatment options, and immuno therapies.

3. Result

The consequences of the research are expected to expose the modern-day landscape of oncology drug development strategies inside the context of customized remedies. They might encompass a comprehensive overview of the exclusive techniques being utilized by researchers and pharmaceutical groups to tailor treatments for individual cancer sufferers primarily based on their genetic and molecular traits. Moreover, the examine may want to highlight the fulfillment charges and challenges related to these techniques, alongside any novel drug development procedures which can be emerging.

4. Discussion

The dialogue phase of the research paper would in all likelihood delve into the consequences of the findings. It would discover the capacity advantages of personalized medicinal drugs in oncology, inclusive of improved remedy effects and decreased damaging outcomes, compared to traditional one-length-fits-all processes. The researchers may additionally speak about the impact of personalized medicine at the price and accessibility of cancer remedies and the way it affects healthcare rules and pointers. Furthermore, the paper may address the challenges and limitations of customized remedies in oncology, including the want for superior genomic profiling technologies, facts privacy concerns, and the improvement of resistance to centered cures. The discussion may additionally touch upon the potential integration of AI and machine-gaining knowledge in reading patient data to optimize remedy selection.

4.1 Novel Oncology Drug Development Strategies

The research ought to potentially find and recommend novel oncology drug improvement strategies that are at the vanguard of personalized medicinal drugs. These strategies would possibly involve progressive combos of targeted cures and immuno therapies, novel drug delivery systems, or the identification of new biomarkers for patient stratification. The dialogue might also spotlight ongoing medical trials and promising preclinical studies that could revolutionize most cancer treatments in the close to future. Standard, this research is probably to offer valuable insights into the current nation of oncology drug improvement inside the technology of customized remedy and offer guidelines for destiny research and improvement to enhance most cancers treatment consequences it may aid healthcare experts, researchers, and policymakers in understanding the ability of personalized medicine and its demanding situations within the discipline of oncology.

10 Conclusion The improved knowledge of tumor biology and genetics in conjunction with improvements in laboratory methodologies and IT structures will retain to make a wonderful impact on oncology drug development. Vital to destiny oncology drug development is the incorporation of biomarkers from the earliest levels and supported with the aid of carried out bioinformatic. further, the use of the latest preclinical models and novel scientific trial designs incorporating intermediate surrogate biomarker endpoints might be vital not best for the higher knowledge of mechanisms of motion of the latest focused pills, but additionally in assist-

ing confident 'move or no-go decisions'. The 'personalized medicinal drug' method regarding the molecular characterization of the tumor and its context inside the micro-environment and immune device, will assist to outline the proper treatment, for the proper affected person at the right time. Growing our know-how on the way to integrate mounted and novel therapeutics in an efficient time frame is critical to improved outcomes for the treatment of solid malignancies.

Acknowledgment

The completion of this research project would not have been possible without the contributions and support of many individuals and organizations. We are deeply grateful to all those who played a role in the success of this project.

We would also like to thank My Mentor Naweed Imam Syed Prof. Department of Cell Biology at the University of Calgary and Dr. Sadaf Ahmed Psychophysiology Lab University of Karachi for their invaluable input and support throughout the research. Their insights and expertise were instrumental in shaping the direction of this project

Declaration of Interest

I at this moment declare that:

I have no pecuniary or other personal interest, direct or indirect, in any matter that raises or may raise a conflict with my duties as a manager of my office Management Conflicts of Interest

The authors declare that they have no conflicts of interest.

Financial Support and Sponsorship

No Funding was received to assist with the preparation of this manuscript

References

1. Hanahan, D. (2000). weinberg rA. The hallmarks of cancer. Cell, 100, 57-70.
2. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. cell, 144(5), 646-674.
3. de BONO, J. S., & Ashworth, A. (2010). Translating cancer research into targeted therapeutics. Nature, 467(7315), 543-549.
4. Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., et al. (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The lancet oncology, 11(6), 521-529.
5. Fukuoka, M., Wu, Y. L., Thongprasert, S., Sunpaweravong, P., Leong, S. S., et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). Journal of clinical oncology, 29(21), 2866-2874.
6. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England journal of medicine, 351(4), 337-345.
7. De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., et al. (2010). Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. Jama, 304(16), 1812-1820.
8. Gysin, S., Salt, M., Young, A., & McCormick, F. (2011). Therapeutic strategies for targeting ras proteins. Genes Cancer 2: 359–372.
9. Biomarkers Definitions Working Group, Atkinson Jr, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., et al. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical pharmacology & therapeutics, 69(3), 89-95.
10. Bartlett, J. M., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., et al. (2001). Evaluating HER2 amplification and overexpression in breast cancer. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 195(4), 422-428.
11. Carlson, B. (2008). HER2 tests: how do we choose?. Biotechnology healthcare, 5(3), 23.
12. Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet, 376(9742), 687-697.
13. Albarello, L., Pecciarini, L., & Doglioni, C. (2011). HER2 testing in gastric cancer. Advances in anatomic pathology, 18(1), 53-59.
14. Hofmann, M., Stoss, O., Gaiser, T., Kneitz, H., Heinmöller, P., et al. (2008). Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. Journal of clinical pathology, 61(1), 89-94.
15. Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., et al. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52(7), 797-805.
16. Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., et al. (2005). Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology, 23(16_suppl), LBA4510-LBA4510.
17. Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British journal of cancer, 95(5), 581-586.
18. Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., et al. (2007). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
19. Herman, S. E., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., et al. (2010). Phosphatidylinositol 3-kinase-δ

inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, The Journal of the American Society of Hematology, 116(12), 2078-2088.
20. Flynn, four years old; Byrd, J.K.; Furman, R.R.; different. (2009) initial records at the scientific pastime of segment 1 take a look at CAL-101, a selective inhibitor of the p110 isoform of phosphatidylinositol three-kinase (PI3K), in patients with sure hematological malignancies. well worth. smooth the residence; 27:15 seconds (upload, § 3543)
21. Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annual review of medicine, 53(1), 615-627.
22. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26), 2507-2516.
23. Hammerman, P. S., Jänne, P. A., & Johnson, B. E. (2009). Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer. Clinical cancer research, 15(24), 7502-7509.
24. Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., et al. (2010). BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science signaling, 3(149), ra84-ra84.
25. Corcoran, R. B., Settleman, J., & Engelman, J. A. (2011). Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget, 2(4), 336.
26. Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer cell, 8(4), 299-309.
27. Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W. T., Duda, D. G., et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer cell, 11(1), 83-95.
28. Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M., et al. (2004). Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer research, 64(18), 6616-6625.
29. Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., et al. (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of clinical oncology, 23(7), 1420-1430.
30. Budd, G. T., Cristofanilli, M., Ellis, M. J., Stopeck, A., Borden, E., et al. (2006). Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clinical Cancer Research, 12(21), 6403-6409.
31. De Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical cancer research, 14(19), 6302-6309.
32. Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
33. Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., et al. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102(1), 276-283.
34. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954.
35. Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences, 106(48), 20411-20416.
36. Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., et al. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British journal of cancer, 97(8), 1139-1145.
37. Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999). Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?. Journal of the National Cancer Institute, 91(15), 1281-1287.
38. Ivy, S. P., Siu, L. L., Garrett-Mayer, E., & Rubinstein, L. (2010). Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research, 16(6), 1726-1736.
39. Cannistra, S. A. (2008). Challenges and pitfalls of combining targeted agents in phase I studies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(22), 3665-3667.
40. Bria, E., Di Maio, M., Carlini, P., Cuppone, F., Giannarelli, D., et al. (2009). Targeting targeted agents: open issues for clinical trial design. Journal of experimental & clinical cancer research, 28(1), 1-7.
41. Chiou, J. F., Tai, C. J., Huang, M. T., Wei, P. L., Wang, Y. H., et al. (2010). Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Annals of surgical oncology, 17, 603-612.
42. Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., et al. (2010). EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. New England Journal of Medicine, 363(18), 1734-1739.
43. Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. cell, 86(3), 353-364.
44. Houben, R., Becker, J. C., Kappel, A., Terheyden, P., Bröcker, E. B., et al. (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. Journal of carcinogenesis, 3, 6.

45. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., ... & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England journal of medicine, 350(23), 2335-2342.